Cipla has dropped its prices of three key cancer medicines.
Kidney cancer:
In a move that will stir up the pot, the company has significantly dropped its prices on generic Sorafenib, used in advanced kidney cancer, from Rs27,950 to Rs6,840.
Sorafenib is the drug on which the Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of this drug, on the payment of a royalty to the innovator company, Bayer.
Natco had pegged its price at about Rs8,900, while Bayer’s price on its branded Sorafenib (Nexavar) is Rs2.8 lakh.
Cipla is bringing down the prices by taking advantage of the economies of scale it has managed to get on the product, a company official told Business Line, adding that oncology is getting a major thrust from the company.
Lung cancer:
Cipla has also dropped its prices on lung cancer drug Gestinib by 60%. Retail prices have come down from Rs10,200 to Rs4,250. The original drug is made by Astra Zeneca under the name Iressa.
Brain tumour:
The third drug that Cipla is dropping the prices is on brain tumour drug Temozolamide in three strengths. Schering makes the original drug.
On the 20-mg pack of five, Cipla has been brought down the prices from Rs1,875 to Rs480; on the 100-mg strength prices are down from Rs8,900 to Rs2,400 and on the 250 mg it is down from Rs20,250 to Rs5,000.
....more info
Kidney cancer:
In a move that will stir up the pot, the company has significantly dropped its prices on generic Sorafenib, used in advanced kidney cancer, from Rs27,950 to Rs6,840.
Sorafenib is the drug on which the Patent Office recently issued a compulsory licence allowing Natco to make a generic copy of this drug, on the payment of a royalty to the innovator company, Bayer.
Natco had pegged its price at about Rs8,900, while Bayer’s price on its branded Sorafenib (Nexavar) is Rs2.8 lakh.
Cipla is bringing down the prices by taking advantage of the economies of scale it has managed to get on the product, a company official told Business Line, adding that oncology is getting a major thrust from the company.
Lung cancer:
Cipla has also dropped its prices on lung cancer drug Gestinib by 60%. Retail prices have come down from Rs10,200 to Rs4,250. The original drug is made by Astra Zeneca under the name Iressa.
Brain tumour:
The third drug that Cipla is dropping the prices is on brain tumour drug Temozolamide in three strengths. Schering makes the original drug.
On the 20-mg pack of five, Cipla has been brought down the prices from Rs1,875 to Rs480; on the 100-mg strength prices are down from Rs8,900 to Rs2,400 and on the 250 mg it is down from Rs20,250 to Rs5,000.
....more info